Journal article
Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis
KA Andrews, C Frost, M Modat, MJ Cardoso, CC Rowe, V Villemagne, NC Fox, S Ourselin, JM Schott
Neurobiology of Aging | ELSEVIER SCIENCE INC | Published : 2016
Open access
Abstract
Increased rates of brain atrophy measured from serial magnetic resonance imaging precede symptom onset in Alzheimer's disease and may be useful outcome measures for prodromal clinical trials. Appropriate trial design requires a detailed understanding of the relationships between β-amyloid load and accumulation, and rate of brain change at this stage of the disease. Fifty-two healthy individuals (72.3 ± 6.9 years) from Australian Imaging, Biomarkers and Lifestyle Study of Aging had serial (0, 18 m, 36 m) magnetic resonance imaging, (0, 18 m) Pittsburgh compound B positron emission tomography, and clinical assessments. We calculated rates of whole brain and hippocampal atrophy, ventricular enl..
View full abstractGrants
Awarded by University of Melbourne
Funding Acknowledgements
Data used in the preparation of this article was obtained from the Australian Imaging Biomarkers and Lifestyle flagship study of ageing (AIBL) which was made available at the ADNI database (www.loni.usc.edu/ADNI). This work was supported by the National Institute for Health Research (NIHR) Queen Square Biomedical Research Unit in Dementia and the UCL/H Biomedical Research Center, and we gratefully acknowledge the support of the Leonard Wolfson Experimental Neurology Centre. The Dementia Research Centre (DRC) is an Alzheimer's Research UK (ARUK) Coordinating Centre and has also received equipment funded by ARUK (www.alzheimersresearchuk.org). For providing the data for this study, the authors thank the AIBL Study Group (www.aibl.csiro.au) which is supported by the Commonwealth Scientific Industrial Research Organization (CSIRO) Flagship Collaboration Fund through the Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship study of Ageing, the Austin Hospital Medical Research Foundation, Neurosciences Victoria, and the University of Melbourne; we also thank the AIBL participants and their carers for their valuable contribution. K. Abigail Andrews is funded by an EPSRC (www.epsrc.ac.uk) PhD studentship. Sebastien Ourselin receives funding from the EPSRC (EP/H046410/1, EP/J020990/1, EP/K005278), the MRC (MR/J01107X/1), the EU-FP7 project VPH-DARE@IT (FP7-ICT-2011-9-601055), the NIHR Biomedical Research Unit (Dementia) at UCL and the National Institute for Health Research University College London Hospitals Biomedical Research Centre (NIHR BRC UCLH/UCL High Impact Initiative- BW.mn.BRC10269); Marc Modat is supported by the UCL Leonard Wolfson Experimental Neurology Centre (PR/ylr/18575); Nick C. Fox is an NIHR Senior Scientist and also holds grants from the National Institute on Aging (NIH) USA (5U01AG024904-10) for work on ADNI. Jonathan M. Schott receives grant funding from ARUK (ARUK-PG2014-1946) and the MRC Dementias Platform UK (MR/L023784/1 and MR/009076/1), and acknowledges the support of the UCL/H Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article.